What is MDClone?
MDClone operates as a specialized technology firm dedicated to unlocking the potential of healthcare data. By providing a platform that facilitates exploration, discovery, and collaboration, the company empowers healthcare providers and researchers to derive actionable insights without compromising patient privacy. Its core technology addresses the persistent challenge of data accessibility in clinical environments, effectively bridging the gap between raw health records and meaningful medical innovation. Through its unique approach to data synthesis and democratization, MDClone serves as a foundational layer for institutions aiming to optimize patient outcomes and streamline operational efficiency.
How much funding has MDClone raised?
MDClone has raised a total of $99M across 3 funding rounds:
Series A
$10M
Series B
$26M
Series C
$63M
Series A (2018): $10M with participation from Lightspeed Venture Partners and OrbiMed
Series B (2019): $26M, investors not publicly disclosed
Series C (2022): $63M supported by Viola Growth and Warburg Pincus
Key Investors in MDClone
Lightspeed Venture Partners
A global multistage venture capital firm that invests in early and growth-stage technology companies across sectors such as enterprise software, fintech, and infrastructure.
OrbiMed
A specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms.
Viola Growth
An Israeli-based technology growth capital fund that specializes in investing in global companies at the expansion phase, providing operational expertise to drive sustainable growth.
What's next for MDClone?
With the recent infusion of capital, MDClone is well-positioned to accelerate its enterprise-level expansion and deepen its footprint in the global digital health market. The strategic focus will likely center on enhancing its synthetic data capabilities and expanding its reach into new geographic territories where data privacy regulations remain a significant barrier to innovation. By leveraging its current financial momentum, the company is poised to further integrate its solutions into the workflows of large-scale health systems, ultimately setting a new standard for how clinical data is utilized in the pursuit of precision medicine and improved population health outcomes.
See full MDClone company page
